Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function.
Rivermark Medical has raised $20.0M in total funding. The most recent round was Series D. The last funding was announced in May 2026.
Rivermark Medical's investors include Andera Partners, Clarevia Ventures, TIME BioVentures, American Century Investments, Cadence Healthcare Ventures.
Rivermark Medical is headquartered in Milwaukee, United States.
Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function.
Rivermark Medical is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Rivermark Medical — Funding & Investors." VCBacked, May 13, 2026, https://www.vcbacked.co/company/rivermark-medical. Accessed October 28, 2026.
VCBacked. (2026). Rivermark Medical — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/rivermark-medical
{{cite web |title=Rivermark Medical — Funding & Investors |url=https://www.vcbacked.co/company/rivermark-medical |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated